A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder

Exclusion Criteria

• •Participant had any known or suspected hypersensitivity to cannabinoids or any of the excipients of the Investigational Medicinal Product (IMP).
• •Participant had a Positive and Negative Symptom Scale total score of \<60 at Day 1.
• •Participant presented with a current clinical picture and/or history that is consistent with:
• •i. delirium or dementia. ii. acute drug induced psychosis. iii. bipolar disorder.
• •Participant was taking more the one AP medication during the study.
• •Female participants of child bearing potential and male participants whose partner was of child bearing potential, unless willing to ensure that they or their partner used effective contraception, for example, oral contraception, double barrier, intra-uterine device, during the study and for three months thereafter (a male condom was not used in conjunction with a female condom).
• •Female participant who was pregnant, lactating, or planning pregnancy during the course of the study and for three months thereafter.
• •Participants who had received an IMP within 30 days prior to the screening visit.
• •Participants who had any other significant disease or disorder which, in the opinion of the investigator, either put the participant at risk because of participation in the study, or may have influenced the result of the study, or the participant's ability to participate in the study.
• •Participant had any abnormalities following a physical examination that, in the opinion of the investigator, prevented the participant from safe participation in the study.
• •Participant was unwilling to abstain from donation of blood during the study.
• •Participant had travelled outside the country of residence during the study.
• •Participant previously randomized into this study.